Hong Kong healthcare stocks continued their upward momentum on August 26, with innovative drug developers taking over the leadership baton from the CXO sector. Cansino Biologics Inc. soared more than 22% during intraday trading, INNOVENT BIO surged over 10% to hit an all-time high, while other notable gainers included IMMUNOTECH-B which climbed 5%.
The Hong Kong Stock Connect Innovative Drug ETF (520880), which invests 100% in innovative drug research and development companies, opened higher and continued to strengthen, with trading volume reaching 444 million yuan by 1:40 PM, already exceeding the previous day's full-day turnover. Meanwhile, the Hong Kong Stock Connect Healthcare ETF (159137), which heavily weights the innovative drug supply chain, saw its intraday price reach a new six-month high.
Two major catalysts drove the sector's performance. First, innovative drug leader INNOVENT BIO delivered better-than-expected interim results. For the first half of 2026, the company reported product revenue of 8.202 billion yuan (up 56.7% year-over-year), driving Non-IFRS net profit to 1.704 billion yuan (up 40.5% year-over-year). Management also unveiled its first-ever revenue guidance of 35-40 billion yuan by 2030, implying a compound annual growth rate of 21.83%-25.12% over the next five years.
Second, Cansino Biologics Inc. announced a strategic partnership with DepusBio for the development of mRNA-based therapeutic tumor vaccines. According to the company's official WeChat account, the two firms formally signed a framework agreement for co-developing personalized mRNA therapeutic tumor vaccines, covering both research and commercialization efforts.
Huayuan Securities expressed strong confidence in the pharmaceutical sector heading into the fourth quarter, noting that innovative drug stocks are likely to drive sector-wide gains on a stock-by-stock basis. The brokerage highlighted that industry-wide prosperity remains high, with CDMO and early-stage research segments showing solid earnings visibility, potentially leading to a "Davis Double Play" for select core assets.
Industrial Securities pointed out that "innovation plus globalization" should remain the core investment theme for the pharmaceutical sector in 2026. The market is shifting from valuation-driven to performance and global commercialization-driven dynamics for innovative drugs. Key catalysts include overseas clinical data readouts, major business development deals, and breakthroughs in new technologies.
For investors seeking comprehensive exposure to the innovative drug supply chain, two T+0 trading instruments are available: the Hong Kong Stock Connect Innovative Drug ETF (520880), which tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index with 100% allocation to R&D-focused companies and approximately 70% in R&D leaders, along with its OTC feeder fund (025221). The Hong Kong Stock Connect Healthcare ETF (159137) tracks the Hong Kong Stock Connect Healthcare Thematic Index with 50% CXO and 20% innovative drug exposure, where WuXi-related companies account for over 38% of holdings, alongside its OTC feeder fund (026922).
Data sources include public information from Shanghai, Shenzhen and Hong Kong exchanges, CSI Index Company, and Hang Seng Index Company, with weight data as of August 25, 2026. Institutional references include Huayuan Securities' August 23 report "Pharmaceutical Weekly: Interim Results Rolling Out, Focus on Traditional Big Pharma Opportunities" and Industrial Securities' August 24 report "Pharmaceutical Biotech Weekly: Personalized Tumor Vaccines Break Through, Continue to Favor Innovative Drug Supply Chain + Innovative Drugs."
Note that ETF funds do not charge sales service fees. When subscribing or redeeming fund shares, the agent broker may charge commissions up to 0.5%, including fees from securities exchanges and registration institutions. Please refer to fund legal documents for complete fee details.
Risk disclosure: The index constituent stocks mentioned are for illustrative purposes only and do not constitute investment advice in any form, nor do they represent the portfolio holdings or trading activities of any fund under the management company. The weights of mentioned stocks in the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index are: INNOVENT BIO 11.42%, IMMUNOTECH-B 7.51%, and Cansino Biologics Inc. 0.39%. In the Hong Kong Stock Connect Healthcare Thematic Index: INNOVENT BIO 2.03% and IMMUNOTECH-B 1.43%. The funds are rated R4 (medium-high risk) and suitable for aggressive (C4) and above investors. Any information in this article is for reference only, and investors must bear responsibility for their own investment decisions. Views, analysis, and forecasts do not constitute investment advice and the fund manager assumes no liability for any losses arising from the use of this content. Past performance does not guarantee future results; investing involves risks.
Comments